Fear of progression (FoP) is frequent in patients with cancer and of high clinical relevance. Despite the often devastating prognosis of brain cancer, FoP has not yet been assessed in neurooncological patients.
The aim of this study was thus the assessment of FoP and its clinical correlates.
In an ambulatory setting, 42 patients with a primary brain tumour completed the Fear of Progression questionnaire FoP-Q-12. Clinical correlates of FoP were assessed via a variety of measures, including patients’ physical state (Karnofsky Performance Status, KPS), cancer-related psychosocial distress (Distress Thermometer, DT), anxiety (General Anxiety Disorder Scale, GAD-7), depression (Patient Health Questionnaire, PHQ-9), Quality of Life (Short Form Health Survey, SF-8), and unmet supportive care needs (Supportive Care Needs Survey, SCNS).
Eighteen patients (42%) suffered from high FoP (i.e. scored ≥ 34 in the FoP-Q-12). According to the 12 items of the FoP-Q-12, the greatest fears were worrying about what would happen to their family and being afraid of severe medical treatments. No sociodemographic variables (e.g. age, gender) or medical tumour characteristics (e.g. tumour malignancy, first or recurrent tumour) were related to FoP. Patients with more severe physical symptoms reported higher FoP. Patients with higher FoP were more anxious, more depressed, reported lower Quality of Life, and suffered from more unmet supportive care needs.
Our results demonstrate that FoP is frequent and of high clinical relevance for neurooncological patients. Its assessment is not sufficiently covered by instruments for assessment of other areas of psychological morbidity (e.g. general anxiety). Moreover, FoP cannot be predicted by objective characteristics of the patients and disease. Thus, the routine screening for FoP is recommended in neurooncological patients. Clinicians should bear in mind that patients with high FoP are likely to suffer from high emotional distress and unmet supportive care needs and initiate treatment accordingly.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
de Robles P, Fiest KM, Frolkis AD, Pringsheim T, Atta C, St. Germaine-Smith C, Day L, Lam D, Jette N (2015) The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro-Oncology 17:776–783. https://doi.org/10.1093/neuonc/nou283
Ownsworth T, Hawkes A, Steginga S, Walker D, Shum D (2009) A biopsychosocial perspective on adjustment and quality of life following brain tumor. Disabil Rehabil 31:1038–1055. https://doi.org/10.1080/09638280802509538
Ostrom QT, Gittleman H, Fulop J et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-Oncology 17(Suppl 4):iv1–iv62. https://doi.org/10.1093/neuonc/nov189
Chochinov HM (2001) Depression in cancer patients. Lancet Oncol 2:499–505. https://doi.org/10.1016/S1470-2045(01)00456-9
Huang J, Zeng C, Xiao J, Zhao D, Tang H, Wu H, Chen J (2017) Association between depression and brain tumor: a systematic review and meta-analysis. Oncotarget 8:94932–94943. https://doi.org/10.18632/oncotarget.19843
Huang ME, Wartella J, Kreutzer J, Broaddus W, Lyckholm L (2001) Functional outcomes and quality of life in patients with brain tumours: a review of the literature. Brain Inj 15(10):843–856. https://doi.org/10.1080/02699050010013653
Goebel S, Stark AM, Kaup L, von Harscher M, Mehdorn HM (2011) Distress in patients with newly diagnosed brain tumours. Psycho-Oncology 20:623–630. https://doi.org/10.1002/pon.1958
Pace A, Metro G, Fabi A (2010) Supportive care in neurooncology. Curr Opin Oncol 22:621–626. https://doi.org/10.1097/CCO.0b013e32833e078c
Salander P (2010) Facilitating interventions and/or relationships in malignant brain tumors. Adv Ther 27:17–27. https://doi.org/10.1007/s12325-010-0003-z
Berg P, Book K, Dinkel A, Henrich G, Marten-Mittag B, Mertens D, Ossner C, Volmer S, Herschbach P (2011) Progredienzangst bei chronischen Erkrankungen. Psychother Psychosom Med Psychol 61:32–37. https://doi.org/10.1055/s-0030-1267927
Dankert A, Duran G, Engst-Hastreiter U et al (2003) Progredienzangst bei Patienten mit Tumorerkrankungen, Diabetes mellitus und entzündlich-rheumatischen Erkrankungen. Rehabilitation 42:155–163. https://doi.org/10.1055/s-2003-40094
Herschbach P, Dinkel A (2014) Fear of progression. In: Goerling U (ed) Psycho-Oncology. Springer, Berlin s.l, pp 11–29
Herschbach P, Berg P, Dankert A, Duran G, Engst-Hastreiter U, Waadt S, Keller M, Ukat R, Henrich G (2005) Fear of progression in chronic diseases: psychometric properties of the Fear of Progression Questionnaire. J Psychosom Res 58:505–511. https://doi.org/10.1016/j.jpsychores.2005.02.007
Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S, Ozakinci G (2013) Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv 7:300–322. https://doi.org/10.1007/s11764-013-0272-z
Koch L, Jansen L, Brenner H, Arndt V (2013) Fear of recurrence and disease progression in long-term (≥ 5 years) cancer survivors- a systematic review of quantitative studies. Psycho-Oncology 22(1):1–11. https://doi.org/10.1002/pon.3022
Lebel S, Tomei C, Feldstain A, Beattie S, McCallum M (2013) Does fear of cancer recurrence predict cancer survivors' health care use? Support Care Cancer 21:901–906. https://doi.org/10.1007/s00520-012-1685-3
Mehnert A, Berg P, Henrich G, Herschbach P (2009) Fear of cancer progression and cancer-related intrusive cognitions in breast cancer survivors. Psycho-Oncology 18:1273–1280. https://doi.org/10.1002/pon.1481
Sarkar S, Scherwath A, Schirmer L, Schulz-Kindermann F, Neumann K, Kruse M, Dinkel A, Kunze S, Balck F, Kröger N, Koch U, Mehnert A (2014) Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT. Bone Marrow Transplant 49:1217–1222. https://doi.org/10.1038/bmt.2014.139
Mehnert A, Koch U, Sundermann C et al (2013) Predictors of fear of recurrence in patients one year after cancer rehabilitation: a prospective study. Acta Oncol (Stockholm, Sweden) 52:1102–1109. https://doi.org/10.3109/0284186X.2013.765063
Hall DL, Luberto CM, Philpotts LL, Song R, Park ER, Yeh GY (2018) Mind-body interventions for fear of cancer recurrence: a systematic review and meta-analysis. Psycho-Oncology 27:2546–2558. https://doi.org/10.1002/pon.4757
Berrett-Abebe J, Cadet T, Pirl W, Lennes I (2015) Exploring the relationship between fear of cancer recurrence and sleep quality in cancer survivors. J Psychosoc Oncol 33:297–309. https://doi.org/10.1080/07347332.2015.1020586
Sarkar S, Sautier L, Schilling G, Bokemeyer C, Koch U, Mehnert A (2015) Anxiety and fear of cancer recurrence and its association with supportive care needs and health-care service utilization in cancer patients. J Cancer Surviv 9:567–575. https://doi.org/10.1007/s11764-015-0434-2
Crist JV, Grunfeld EA (2013) Factors reported to influence fear of recurrence in cancer patients: a systematic review. Psycho-Oncology 22:978–986. https://doi.org/10.1002/pon.3114
Champagne A, Ivers H, Savard J (2018) Utilization of health care services in cancer patients with elevated fear of cancer recurrence. Psycho-Oncology 27:1958–1964. https://doi.org/10.1002/pon.4748
Shim E-J, Shin Y-W, Oh D-Y, Hahm BJ (2010) Increased fear of progression in cancer patients with recurrence. Gen Hosp Psychiatry 32:169–175. https://doi.org/10.1016/j.genhosppsych.2009.11.017
Mehnert A, Herschbach P, Berg P, Henrich G, Koch U (2006) Fear of progression in breast cancer patients – validation of the short form of the fear of progression questionnaire (FoP-Q-SF). Z Psychosom Med Psychother 52:274–288. https://doi.org/10.13109/zptm.2006.52.3.274
Mehnert A, Müller D, Lehmann C, Koch U (2006) Die deutsche Version des NCCN Distress-Thermometers. Z Psychiatr Psychol Psychother 54:213–223. https://doi.org/10.1024/1661-4722.214.171.124
National Comprehensive Cancer Network (NCCN) (2003) Distress management. Clinical practice guidelines. J Natl Compr Cancer Netw 1:344–374
Spitzer RL, Kroenke K, Williams JBW, Löwe B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166:1092–1097. https://doi.org/10.1001/archinte.166.10.1092
Löwe B, Decker O, Müller S, Brähler E, Schellberg D, Herzog W, Herzberg PY (2008) Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care 46:266–274. https://doi.org/10.1097/MLR.0b013e318160d093
Löwe B, Spitzer RL, Zipfel S, Herzog W (2000) Der Gesundheitsfragebogen für Patienten (PHQ-D). Manual und Testunterlagen
Spitzer RL (1999) Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA 282:1737. https://doi.org/10.1001/jama.282.18.1737
Ware JE, Kosinski M, Dewey JE, Gandek B, Ware JE, Kisinski M, Ware J, Dewey J (2008) How to score and interpret single-item health status measures. A manual for users of the SF-8™ Health Survey
Bonevski B, Sanson-Fisher R, Girgis A, Burton L, Cook P, Boyes A, the Supportive Care Review Group (2000) Evaluation of an instrument to assess the needs of patients with cancer. Cancer 88:217–225. https://doi.org/10.1002/(SICI)1097-0142(20000101)88:1<217:AID-CNCR29>3.0.CO;2-Y
Hinz A, Mehnert A, Ernst J, Herschbach P, Schulte T (2015) Fear of progression in patients 6 months after cancer rehabilitation- a validation study of the fear of progression questionnaire FoP-Q-12. Support Care Cancer 23:1579–1587. https://doi.org/10.1007/s00520-014-2516-5
Hanprasertpong J, Geater A, Jiamset I, Padungkul L, Hirunkajonpan P, Songhong N (2017) Fear of cancer recurrence and its predictors among cervical cancer survivors. J Gynecol Oncol 28:e72. https://doi.org/10.3802/jgo.2017.28.e72
Goebel S, Kaup L, Mehdorn HM (2011) Measuring preoperative anxiety in patients with intracranial tumors: the Amsterdam preoperative anxiety and information scale. J Neurosurg Anesthesiol 23:297–303. https://doi.org/10.1097/ANA.0b013e318222b787
Goebel S, Mederer D, Mehdorn HM (2018) Surgery-related coping in surgery patients with intracranial tumors. World Neurosurg 116:e775–e782. https://doi.org/10.1016/j.wneu.2018.05.091
Goebel S, Strenge H, Mehdorn HM (2012) Acute stress in patients with brain cancer during primary care. Support Care Cancer 20(7):1425–1434. https://doi.org/10.1007/s00520-011-1225-6
Sharpe L, Curran L, Butow P, Thewes B (2018) Fear of cancer recurrence and death anxiety. Psycho-Oncology 27:2559–2565. https://doi.org/10.1002/pon.4783
Salander P (1996) Brain tumor as a threat to life and personality. J Psychosoc Oncol 14:1–18. https://doi.org/10.1300/J077v14n03_01
Cohee AA, Adams RN, Johns SA, von Ah D, Zoppi K, Fife B, Monahan PO, Stump T, Cella D, Champion VL (2017) Long-term fear of recurrence in young breast cancer survivors and partners. Psycho-Oncology 26:22–28. https://doi.org/10.1002/pon.4008
Ganz PA, Kwan L, Stanton AL, Krupnick JL, Rowland JH, Meyerowitz BE, Bower JE, Belin TR (2004) Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst 96:376–387
Zimmermann T, Herschbach P, Wessarges M et al (2011) Fear of progression in partners of chronically ill patients. Behav Med (Washington, D.C.) 37:95–104. https://doi.org/10.1080/08964289.2011.605399
Mellon S, Kershaw TS, Northouse LL, Freeman-Gibb L (2007) A family-based model to predict fear of recurrence for cancer survivors and their caregivers. Psycho-Oncology 16:214–223. https://doi.org/10.1002/pon.1074
The authors are grateful to Anja Mehnert for providing the SCNS and to Hannah Schmale for the valuable support during data collection.
This study was performed in accordance with the Helsinki standard and approved by the local ethics committee.
Conflict of interest
The authors declare that they have no conflict of interest.
We have full control of all primary data and agree to allow the journal to review the data if requested.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Goebel, S., Mehdorn, H.M. Fear of disease progression in adult ambulatory patients with brain cancer: prevalence and clinical correlates. Support Care Cancer 27, 3521–3529 (2019). https://doi.org/10.1007/s00520-019-04665-9
- Brain tumour
- Fear of cancer progression